Drug intelligence / Profile preview

IAL-F

Development stage: Unknown
Lead developer: Fidia Farmaceutici
Modality: Recombinant Proteins and Enzymes
Administration: Intraocular

Overview

IAL-F is a cohesive ophthalmic viscoelastic device (OVD) containing 1.8% sodium hyaluronate derived from animal sources and is used primarily in cataract surgery (phacoemulsification with intraocular lens implantation) to maintain anterior chamber space, protect corneal endothelium, and facilitate surgical maneuvers. It is metabolized in the human body and has demonstrated efficacy in protecting against corneal endothelial cell loss, with safety comparable to other OVDs. The product is manufactured by Fidia Farmaceutici for use in ophthalmological procedures[3].

Brand names: IAL-F
Other names: IAL-F

Targets

RHAMM (Hyaluronan-mediated motility receptor)STAB2 (Stabilin-2)CD44 (CD44 antigen)ICAM1 (Intercellular Adhesion Molecule 1)

Beyond the preview

Go deeper on IAL-F.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IAL-F.

Explore the full profile